Preeclampsia Market Report and Forecast 2024-2032

Preeclampsia Market Report and Forecast 2024-2032


Preeclampsia Market Report and Forecast 2024-2032

Preeclampsia Market Outlook

The preeclampsia market size is anticipated to grow at a CAGR of 1.8% during the forecast period of 2024-2032, driven by advancements in early detection and monitoring along with growing hypertension prevalence across major markets.

Preeclampsia: Introduction

Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to organ systems, often the kidneys. It usually occurs after 20 weeks of pregnancy in women whose blood pressure had been normal. Symptoms include persistent headaches, blurred vision, and abdominal pain. Preeclampsia can lead to serious, even fatal, complications for both mother and baby if not properly managed. Treatment often involves medication to lower blood pressure and, when necessary, early delivery of the baby.

Key Trends in the Preeclampsia Market

There's a growing emphasis on early detection of preeclampsia through advanced screening methods. This includes the development of new biomarkers and diagnostic tests that can identify women at high risk earlier in their pregnancies.

There has been increasing research, focusing on preventative measures, such as the use of low-dose aspirin in high-risk women, along with dietary and lifestyle interventions to reduce the incidence of preeclampsia.

Efforts are underway to develop targeted therapies that address the underlying pathophysiology of preeclampsia, aiming to treat the condition more effectively and with fewer side effects.

The use of digital health tools, such as telehealth platforms and remote monitoring devices, is on the rise. These tools assist in closely monitoring blood pressure and other vital signs in pregnant women, especially those at risk of preeclampsia.

There's an increased focus on educating pregnant women about the signs and symptoms of preeclampsia, emphasizing the importance of regular prenatal care and timely reporting of symptoms.

Global collaboration among research institutions, healthcare providers, and pharmaceutical companies is enhancing the development of new treatments and management strategies.

The management of preeclampsia is being increasingly recognized as a critical aspect of global maternal health initiatives, leading to more funding and resources being allocated to address this condition.

Personalized medicine, considering individual risk factors such as genetics, pre-existing conditions, and pregnancy history, is gaining traction in managing preeclampsia.

Preeclampsia Market Segmentation

Market Breakup by Treatment
  • Medication to Lower B.P.
  • Corticosteroids
  • Anticonvulsants Medication
Market Breakup by Disease Type
  • Mild Preeclampsia
  • Severe Preeclampsia
Market Breakup by End User
  • Hospitals
  • Clinics
  • Others
Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
Preeclampsia Market Overview

In North America, there is a high level of awareness and advanced healthcare infrastructure, leading to better screening, early detection, and management of preeclampsia. The focus is on integrating new diagnostic methods and treatment protocols. Research and development in this field are also robust, with ongoing clinical trials and studies.

European countries benefit from strong healthcare systems, which facilitate comprehensive prenatal care, including screening and management of preeclampsia. There's a significant focus on research and adherence to established guidelines for preeclampsia management. Some countries in Europe are leaders in developing new diagnostic and treatment methods.

In Japan, a varied approach is seen due to diverse healthcare systems across countries. The management of preeclampsia aligns with global standards, but in many developing countries, challenges such as limited access to prenatal care and low awareness can impact the management of the condition. Efforts are being made to improve prenatal care and education about preeclampsia.

Preeclampsia Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Thermo Fisher Scientific Inc.
  • Baxter
  • Bayer AG
  • Merck & Co., Inc
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthcare GmbH
  • PerkinElmer Inc
  • Sera Prognostics
  • DRG Instruments GMBH
  • Metabolomic Diagnostics
  • Diabetomics, Inc.
  • Hitachi Ltd
  • Cardinal Health Inc
  • BioMerieux SA
  • Fujirebio Diagnostics
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Preeclampsia Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Preeclampsia Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Preeclampsia Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Preeclampsia Epidemiology Forecast (2017-2032)
5.3.1 Germany Preeclampsia Epidemiology Forecast (2017-2032)
5.3.2 France Preeclampsia Epidemiology Forecast (2017-2032)
5.3.3 Italy Preeclampsia Epidemiology Forecast (2017-2032)
5.3.4 Spain Preeclampsia Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Preeclampsia Epidemiology Forecast (2017-2032)
5.4 Japan Preeclampsia Epidemiology Forecast (2017-2032)
6 Preeclampsia Market Overview – 7MM
6.1 Preeclampsia Market Historical Value (2017-2023)
6.2 Preeclampsia Market Forecast Value (2024-2032)
7 Preeclampsia Market Landscape – 7MM
7.1 Preeclampsia Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Preeclampsia Product Landscape
7.2.1 Analysis by Products
7.2.2 Analysis by Indications
7.2.3 Analysis by Route of Administration
8 Preeclampsia Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Preeclampsia Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Preeclampsia Market Segmentation – 7MM
11.1 Preeclampsia Market by Treatment
11.1.1 Market Overview
11.1.2 Medication to Lower B.P.
11.1.3 Corticosteroids
11.1.4 Anticonvulsants Medication
11.2 Preeclampsia Market by Disease Type
11.2.1 Market Overview
11.2.2 Mild Preeclampsia
11.2.3 Severe Preeclampsia
11.3 Preeclampsia Market by End User
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Clinics
11.3.4 Others
11.4 Preeclampsia Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
12 United States Preeclampsia Market
12.1 Preeclampsia Market Historical Value (2017-2023)
12.2 Preeclampsia Market Forecast Value (2024-2032)
12.3 Preeclampsia Market by Disease Type
12.4 Preeclampsia Market by Treatment Type
13 EU-4 and United Kingdom Preeclampsia Market
13.1 Preeclampsia Market Historical Value (2017-2023)
13.2 Preeclampsia Market Forecast Value (2024-2032)
13.3 Germany Preeclampsia Market Overview
13.3.1 Preeclampsia Market by Disease Type
13.3.2 Preeclampsia Market by Treatment Type
13.4 France Preeclampsia Market Overview
13.4.1 Preeclampsia Market by Disease Type
13.4.2 Preeclampsia Market by Treatment Type
13.5 Italy Preeclampsia Market Overview
13.5.1 Preeclampsia Market by Disease Type
13.5.2 Preeclampsia Market by Treatment Type
13.6 Spain Preeclampsia Market Overview
13.6.1 Preeclampsia Market by Disease Type
13.6.2 Preeclampsia Market by Treatment Type
13.7 United Kingdom Preeclampsia Market Overview
13.7.1 Preeclampsia Market by Disease Type
13.7.2 Preeclampsia Market by Treatment Type
14 Japan Preeclampsia Market
14.1 Preeclampsia Market Historical Value (2017-2023)
14.2 Preeclampsia Market Forecast Value (2024-2032)
14.2.1 Preeclampsia Market by Disease Type
14.2.2 Preeclampsia Market by Treatment Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Thermo Fisher Scientific Inc.
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 Baxter
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Bayer AG
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Merck & Co., Inc
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 F. Hoffmann-La Roche Ltd
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 Siemens Healthcare GmbH
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 PerkinElmer Inc
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Sera Prognostics
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 DRG Instruments GMBH
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 Metabolomic Diagnostics
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Diabetomics, Inc.
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 Hitachi Ltd
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Cardinal Health Inc
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 BioMerieux SA
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
20.15 Fujirebio Diagnostics
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisition
20.15.5 Certifications
21 Preeclampsia Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings